CA-SYSDIG
13.1.2022 17:56:06 CET | Business Wire | Press release
Sysdig, Inc., the unified container and cloud security leader, today announced that Gerald Combs, the Wireshark creator and project leader, has joined the company. Wireshark, an open source tool, is the world’s foremost and widely-used traffic protocol analyzer with more than 60 million downloads in the last 5 years, an average of one million per month. Loris Degioanni, CTO and Founder of Sysdig, partnered with Gerald to launch Wireshark more than 15 years ago. Gerald joins Sysdig’s open source team, which is a significant contributor to many open source projects, including Falco, eBPF, Sysdig open source, Sysdig Inspect, and other tools and libraries. With Gerald joining, Sysdig assumes responsibility for sponsoring and managing the Wireshark community and extending Wireshark’s use cases to the cloud ecosystem.
Wireshark is an open source GUI network package capturing tool that enables teams to monitor network traffic, learn protocols and packet basics, and troubleshoot network problems. For network admins, Wireshark is the de facto standard for checking health and security at a microscopic level. Wireshark takes packet captures and saves them for later viewing. Teams can filter through that traffic to find evidence from an incident. With more than 1,900 contributors, the number of integrations continues to expand. Adoption is broad as Wireshark can be used consistently across nearly any environment, including Windows, Linux, and macOS, among others.
“It’s amazing to see the lasting heritage of Wireshark, led by Gerald. You can guarantee most of the Fortune 2000 are actively using Wireshark,” said Loris Degioanni, CTO and Founder, Sysdig. “I am excited to be reunited with Gerald and to advance the project in the same way Sysdig supports Falco and the Sysdig open source project. This move ensures Wireshark will continue to innovate. Our goal at Sysdig is to empower Wireshark.”
The Importance of Healthy Open Source Projects
The Log4j and OpenSSL vulnerabilities have shown that large and small organizations rely on open source projects and major issues arise when critical vulnerabilities are found in these tools. Log4j spotlighted the importance of maintaining open source projects. Continuing to maintain the project’s health is of the utmost importance considering the widespread adoption of Wireshark.
The Wireshark Story
While studying network analyzers and creating a popular open source tool while working on his PhD in Italy, Loris was invited to the United States to do research on packets, which is where he met Gerald. Gerald joined Loris at CACE Technologies in the early 2000’s, where they collaborated and grew Wireshark. CACE Technologies was later acquired and since that time, Gerald has focused on growing the tool and ensuring Wireshark and its community have the resources needed to thrive.
“I am excited to be reunited with Loris and explore the opportunity we have to expand Wireshark to the cloud,” said Gerald Combs, Director of Open Source Projects, Sysdig. “My move to Sysdig and the subsequent move for Wireshark will give Wireshark the corporate sponsor it needs to continue moving forward. This is a significant milestone for Wireshark and with Sysdig’s backing, we will have the assistance we need to continue to evolve use cases for Wireshark.”
The Wireshark Future
Sysdig will ensure the community has the backing it needs, including supporting Gerald as the leader of the community, ensuring Wireshark has the resources needed to operate, and sponsoring SharkFest. Sysdig has an open source team that will contribute to Wireshark. Reunited, Gerald and Loris will investigate new innovative ways to address challenges with securing the cloud.
Sysdig’s Commitment to Open Source
Sysdig was founded as an open source company and the Sysdig platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source Sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the CNCF in 2018, is now an incubation-level hosted project with more than 40 million downloads.
Resources
- Read Loris’ blog: Sysdig Welcomes Gerald and the Wireshark Community .
- Read Gerald's blog: We Have a New Sponsor .
- Visit Wireshark.org .
- Visit Sysdig.com .
About Sysdig
Sysdig is driving the standard for securing the cloud, empowering organizations to confidently secure containers, Kubernetes, and cloud services. The Sysdig platform enables teams to secure the build, detect and respond to runtime threats, and continuously manage cloud configurations, permissions and compliance. Sysdig is a SaaS platform built on an open source stack that includes Falco and Sysdig open source, the open standards for runtime threat detection and response. The largest and most security conscious companies rely on Sysdig for container and cloud security. sysdig.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom